Stay updated on Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant note regarding the modernization of ClinicalTrials.gov data ingest has been deleted.
    Difference
    0.9%
    Check dated 2025-07-04T03:53:30.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    20 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    0.7%
    Check dated 2025-06-19T19:20:25.000Z thumbnail image
  4. Check
    27 days ago
    No Change Detected
  5. Check
    34 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.1%
    Check dated 2025-06-05T08:50:01.000Z thumbnail image
  6. Check
    41 days ago
    Change Detected
    Summary
    The web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    1%
    Check dated 2025-05-29T05:47:54.000Z thumbnail image
  7. Check
    70 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.
    Difference
    0.1%
    Check dated 2025-04-30T13:48:25.000Z thumbnail image
  8. Check
    84 days ago
    Change Detected
    Summary
    The webpage has been updated to reflect a new version of a clinical study on metastatic breast cancer, including a change in the principal investigator and the addition of specific treatment details. The study now emphasizes the use of Pembrolizumab in combination with HER2 Bispecific Antibody Armed Activated T-Cell infusions.
    Difference
    45%
    Check dated 2025-04-16T01:35:33.000Z thumbnail image

Stay in the know with updates to Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial page.